A Phase 1/2, open-label study of PD-1 knockout tumor-infiltrating lymphocytes (IOV-4001) in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Iovance Biotherapeutics, Inc
Start Date
June 6, 2023
End Date
February 24, 2028
Administered By
Duke Cancer Institute
Awarded By
Iovance Biotherapeutics, Inc
Start Date
June 6, 2023
End Date
February 24, 2028